X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.

Facing the first fine in its 29-year history, the drug maker Genzyme turned to Covington & Burling and Hogan Lovells for counsel in striking a proposed settlement with the federal government over allegedly contaminated drugs, court records show.

Under the terms of the proposed consent decree, Cambridge, Mass.–based Genzyme, which specializes in expensive drugs aimed at treating rare genetic disorders, will pay a $175 million penalty and submit to a strict regime of government oversight that could last up to eight years, according to the Boston Globe and The Associated Press.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]

 
Reprints & Licensing
Mentioned in a Law.com story?

License our industry-leading legal content to extend your thought leadership and build your brand.

 

ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.